Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Lancet Neurol
    May 2022
  1. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    >> Share

    April 2022
  2. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    >> Share

  3. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.
    >> Share

    February 2022
  4. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    >> Share

  5. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.
    >> Share

    January 2022
  6. KANTARCI K
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.
    >> Share

    December 2021
  7. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.
    >> Share

    November 2021
  8. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    >> Share

  9. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    >> Share

  10. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    >> Share

  11. DECARLI C
    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.
    >> Share

    September 2021
  12. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    >> Share

  13. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.
    >> Share

    August 2021
  14. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    >> Share

  15. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.
    >> Share

  16. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    >> Share

    July 2021
  17. THE LANCET NEUROLOGY
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.
    >> Share

  18. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    >> Share

    April 2021
  19. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    >> Share

  20. JAGUST WJ
    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.
    >> Share

    March 2021
  21. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    >> Share

    January 2021
  22. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    >> Share

  23. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.
    >> Share

  24. THE LANCET NEUROLOGY
    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.
    >> Share

    November 2020
  25. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    >> Share

  26. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.
    >> Share

    October 2020
  27. CONDELLO C, DeGrado WF, Prusiner SB
    Prion biology: implications for Alzheimer's disease therapeutics.
    Lancet Neurol. 2020;19:802-803.
    >> Share

  28. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    >> Share

    July 2020
  29. KELLAR D, Craft S
    Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.
    Lancet Neurol. 2020 Jul 27. pii: S1474-4422(20)30231.
    >> Share

    June 2020
  30. QUIROZ YT, Zetterberg H, Reiman EM, Chen Y, et al
    Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.
    Lancet Neurol. 2020;19:513-521.
    >> Share

  31. MASTERS CL
    Major risk factors for Alzheimer's disease: age and genetics.
    Lancet Neurol. 2020;19:475-476.
    >> Share

    May 2020
  32. KARIKARI TK, Pascoal TA, Ashton NJ, Janelidze S, et al
    Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Lancet Neurol. 2020;19:422-433.
    >> Share

  33. MD JH
    Can we trust The End of Alzheimer's?
    Lancet Neurol. 2020;19:389-390.
    >> Share

  34. JACK CR JR
    The transformative potential of plasma phosphorylated tau.
    Lancet Neurol. 2020;19:373-374.
    >> Share

    April 2020
  35. MCMANUS RM, Heneka MT
    T cells in Alzheimer's disease: space invaders.
    Lancet Neurol. 2020;19:285-287.
    >> Share

    March 2020
  36. JESSEN F, Amariglio RE, Buckley RF, van der Flier WM, et al
    The characterisation of subjective cognitive decline.
    Lancet Neurol. 2020;19:271-278.
    >> Share

    February 2020
  37. SCHNEIDER L
    A resurrection of aducanumab for Alzheimer's disease.
    Lancet Neurol. 2020;19:111-112.
    >> Share

  38. CRYAN JF, O'Riordan KJ, Sandhu K, Peterson V, et al
    The gut microbiome in neurological disorders.
    Lancet Neurol. 2020;19:179-194.
    >> Share

    January 2020
  39. ANDREWS SJ, Fulton-Howard B, Goate A
    Interpretation of risk loci from genome-wide association studies of Alzheimer's disease.
    Lancet Neurol. 2020 Jan 24. pii: S1474-4422(19)30435.
    >> Share

  40. JACK CR JR
    Preclinical Alzheimer's disease: a valid concept.
    Lancet Neurol. 2020;19:31.
    >> Share

  41. PETERS R, Anderson CS
    Advancing dementia prevention through effective blood pressure control.
    Lancet Neurol. 2020;19:25-27.
    >> Share

    November 2019
  42. DING J, Davis-Plourde KL, Sedaghat S, Tully PJ, et al
    Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies.
    Lancet Neurol. 2019 Nov 6. pii: S1474-4422(19)30393.
    >> Share

    August 2019
  43. LANE CA, Barnes J, Nicholas JM, Sudre CH, et al
    Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.
    Lancet Neurol. 2019 Aug 20. pii: S1474-4422(19)30228.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016